Sugi Predict

Sugi Predict / Compounds / SCHEMBL4092096

SCHEMBL4092096

SCHEMBL4092096

O=C(O)CCNC(=O)c1ccc(C(NC(=O)Nc2cccc([N+](=O)[O-])c2)c2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 2/20 0.67
▸ RAB9A P51151 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ EPHX2 P34913 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ POLB P06746 3/20 0.42
▸ PGR P06401 1/20 0.42
▸ AR P10275 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ DDX3X O00571 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ CTDSP1 Q9GZU7 1/20 0.41
▸ BAZ1A Q9NRL2 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652649 0.87 GCGR (0.50) GCGRRAB9ANPC1EPHX2GAA
SCHEMBL2650399 0.87 GCGR (0.50) GCGRRAB9ANPC1EPHX2POLB
SCHEMBL6750387 0.87 GCGR (0.50) GCGREPHX2CYP2D6
SCHEMBL2651718 0.87 GCGR (0.50) GCGRRAB9ANPC1EPHX2MAPT
SCHEMBL2653146 0.87 GCGR (0.50) GCGRNPC1EPHX2MAPTGAA
SCHEMBL2652582 0.87 GCGR (0.51) GCGREPHX2L3MBTL1MEN1KMT2A
SCHEMBL2650221 0.86 GCGR (0.50) GCGRRAB9ANPC1EPHX2MAPT
SCHEMBL2658771 0.85 GCGR (0.53) GCGREPHX2CYP2D6
SCHEMBL2658281 0.85 GCGR (0.50) GCGREPHX2POLBHTTCYP2D6
SCHEMBL2651304 0.85 GCGR (0.48) GCGREPHX2L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885RAB9A 2980/4885NPC1 1959/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885RAB9A 2980/4885NPC1 1959/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885RAB9A 2980/4885NPC1 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.